Aptevo Therapeutics (APVO) Debt to Equity (2016 - 2022)
Aptevo Therapeutics (APVO) has disclosed Debt to Equity for 8 consecutive years, with $0.19 as the latest value for Q4 2022.
- Quarterly Debt to Equity fell 98.48% to $0.19 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $0.19 through Dec 2022, down 98.48% year-over-year, with the annual reading at $0.19 for FY2022, 98.48% down from the prior year.
- Debt to Equity hit $0.19 in Q4 2022 for Aptevo Therapeutics, down from $0.25 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $12.64 in Q4 2021 to a low of -$0.82 in Q1 2022.
- Historically, Debt to Equity has averaged $1.98 across 5 years, with a median of $0.69 in 2019.
- Biggest five-year swings in Debt to Equity: soared 1046.58% in 2020 and later crashed 158.02% in 2022.
- Year by year, Debt to Equity stood at $0.63 in 2018, then surged by 164.56% to $1.68 in 2019, then decreased by 9.99% to $1.51 in 2020, then skyrocketed by 737.39% to $12.64 in 2021, then tumbled by 98.48% to $0.19 in 2022.
- Business Quant data shows Debt to Equity for APVO at $0.19 in Q4 2022, $0.25 in Q3 2022, and $0.19 in Q2 2022.